3 completed, 1 withdrawn. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Completed 3, Withdrawn 1 |
Follow Protalix: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Efficacy, & PK of PRX-102 in Patients With Fabry Disease Administered Intravenously Every 4 Weeks Pegunigalsidase alfa - Fabry Disease | Phase 3 | Completed | Protalix | 30 | 2017-07-10 | 2023-09-13 |
| Study to Evaluate the Safety and EffIcacy of PRX-102 on Gastrointestinal Symptoms in Naïve Fabry Disease PRX-102, Placebo - Fabry Disease | Phase 3 | Withdrawn | Protalix | 2017-07-01 | 2018-01-08 | |
| Safety and Efficacy of PRX-102 in Patients With Fabry Disease Currently Treated With REPLAGAL® (Agalsidase Alfa) PRX-102 (pegunigalsidase alfa) - Fabry Disease | Phase 3 | Completed | Protalix | 22 | 2017-05-17 | 2023-09-13 |
| Study of the Safety and Efficacy of PRX-102 Compared to Agalsidase Beta on Renal Function PRX-102 (pegunigalsidase alfa), agalsidase beta - Fabry Disease | Phase 3 | Completed | Protalix | 78 | 2016-06-01 | 2023-09-13 |
Fabry Disease (4) · Abdominal Pain (1) · Diarrhea (1) · Proteinuria (1)
agalsidase beta (1)
Czechia (3) · Norway (3) · United Kingdom (3) · Italy (2) · Netherlands (2) · Slovenia (2) · United States (2) · Australia (1) · Belgium (1) · Canada (1) · Denmark (1) · Finland (1) · France (1) · Hungary (1) · Spain (1)